Allogene
Therapeutics develops an allogeneic chimeric antigen receptor for the treatment of cancer... Read moreAllogene
Therapeutics develops an allogeneic chimeric antigen receptor for the treatment of cancer... Read more
2017
PublicNASDAQALLO
News
May 14, 2026
Seeking Alpha
Allogene: Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Apr 21, 2026
GlobalNewswire
Press Release: Allogene : Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Apr 20, 2026
GlobalNewswire
Press Release: Allogene : Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Apr 15, 2026
Seeking Alpha
Allogene: Allogene Therapeutics prices $175M stock offering at $2 per share
Apr 14, 2026
Seeking Alpha
Allogene: Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow
Apr 13, 2026
BioSpace
Allogene: Allogene stock sails after CAR T clears residual lymphoma in early data cut
Apr 13, 2026
STAT News
Allogene: STAT+: Allogene Therapeutics' CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients
Apr 13, 2026
Benzinga
Allogene: Allogene Therapeutics Stock Hits 52-Week High - Here's Why
Mar 13, 2026
Owler
Allogene Therapeutics, Inc.: Allogene's employee count changed from 229 in Dec 2024 to 152 in Dec 2025
Mar 12, 2026
Marketscreener
Allogene: Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025
Allogene Competitors
1
2
3
4
5
6
7
8
9
10